Skip to content

Can a New AI Tool Help ECGs Detect PH Earlier?

Search Clinical Trials

Trial Objectives


Interstitial lung disease can be associated with a number of other lung diseases, including pulmonary hypertension (PH), or high blood pressure in the lungs. Researchers are investigating a non-invasive screening called an electrocardiogram (ECG), paired with new AI tools, to determine if it can detect PH in ILD patients sooner than current diagnostic tools. Earlier diagnosis helps patients get treatment sooner and, potentially, have better outcomes.

Volunteers in this study will receive a 12-lead ECG test and will be scored for potential risk of developing PH. If they score higher risk, they will receive a medical exam and will be monitored for 6 months. Participants will receive continued medical care to evaluate who develops symptoms of PH within that period. The data collected will help researchers continue to improve these diagnostic tools for identifying PH in ILD patients.

Who Can Participate


Adults 18+ with a diagnosis of ILD.

Age: 18+ Gender: Any

Estimated Time Commitment


2-3 visits over about 6 months

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Not Available

Trial Contact


For more information, contact:

Adrea Arthofer
303.270.8608

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Tempus AI, Inc.

Principal Investigators

Joshua J. Solomon

Joshua J. Solomon, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required